Key clinical point: Adjuvant monotherapy may improve surgical outcomes for patients with early-stage NSCLC.
Major finding: The major pathological response rate in the efficacy population was 19%.
Study details: Interim analysis of a phase 2 study with 101 of 180 planned patients enrolled.
Disclosures: The study is supported by Genentech. Dr. Kwiatkowski disclosed research funding and a consulting or advisory role for the company. Dr. Diehn reported stock ownership, consulting, research funding, and travel expenses from various companies.
Kwiatkowski DJ et al. ASCO 2019, Abstract 8503.